Welcome!

Web 2.0 Authors: Roger Strukhoff, Bob Gourley

News Feed Item

Fogarty Institute for Innovation Accepting Applications for Advanced Endovascular Training Fellowship

--Deadline for applications February 15, 2013--

MOUNTAIN VIEW, Calif., Dec. 12, 2012 /PRNewswire/ -- Following a successful inaugural year, the Fogarty Institute for Innovation announced today that it is accepting applications for its Advanced Endovascular Training Fellowship.  This unique clinical training program, which will begin on July 8, 2013, provides Fellows with broad exposure to all aspects of endovascular patient care, with an emphasis on interventional training. Fellows will also have the opportunity to engage with the Fogarty Institute's early-stage medical device start-up companies and assist in the process of developing technologies to improve patient care.

"The Fellowship provides physicians with an unparalleled and holistic educational and clinical training experience," said James Joye, D.O., director of the fellowship program and chief medical officer of the Fogarty Institute. "Not only are they working side-by-side with experts in endovascular specialty areas, but they are providing clinical feedback to early stage technology innovation in the Fogarty Institute and learning about the business and systems of a community hospital with El Camino Hospital senior leadership."

In addition to providing a salary and benefits to support the Fellows' education and training, the Fogarty Institute will match each Fellow with clinical advisors from different clinical disciplines, as well as an innovation and entrepreneurship advisor from the Fogarty Institute. During the fellowship, each Fellow will be encouraged to conduct research in their area of interest and author publications based on their findings.

Criteria for the fellowship include board-certified or board-eligible training in interventional cardiology, interventional radiology, vascular surgery or cardiovascular surgery.  A California Physicians License will be required only for those selected into the program. Interested physicians may apply online by Friday, February 15, 2013, at www.fogartyinstitute.org/fellowship.html. Those selected will be notified by the end of February.

For fellowship inquiries, contact the Fogarty Institute for Innovation at (650) 962-4560 or [email protected].

The program is made possible through generous support of the Heart & Vascular Institute of El Camino Hospital and VIVA Physicians.

About The Fogarty Institute for Innovation
The Fogarty Institute for Innovation is a non-profit 501(c)3 organization that serves to energize the process of medical technology innovation. Its educational activities involve teaching the skills and methodology necessary for medical innovators to translate their ideas into new patient therapies. The Institute and its affiliated Taft Center for Clinical Research are located on the campus of El Camino Hospital in Mountain View, Calif.

About El Camino Hospital
El Camino Hospital is an acute-care, 443-bed, nonprofit and locally governed organization with campuses in Mountain View and Los Gatos, Calif.  In addition to state-of-the-art emergency departments, key medical specialties include heart and vascular, cancer care, urology, orthopedic and spine, genomic medicine, and the only Women's Hospital in Northern California.  The hospital is recognized as a national leader in the use of health information technology and wireless communications, and has been awarded the Gold Seal of Approval from The Joint Commission as a Primary Stroke Center as well as back-to-back ANCC Magnet Recognitions for Nursing Care.

To learn more, visit our website, find us on Facebook, follow us on Twitter, or view our videos on YouTube. For a physician referral, visit our website or call the El Camino Health Line at 800-216-5556.

SOURCE Fogarty Institute for Innovation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.